A partnership with the proteasome: the destructive nature of GSK3

Search results

• Finished

  Contribution by NRF2 Upregulation to Lung Carcinogenesis and the Possible Therapeutic Value of NRF2 Inhibition by GSK-3 (Joint with Universities of St Andrews, Edinburgh and Pennsylvania)

  Dinkova-Kostova, A. (Investigator), Hayes, J. (Investigator), Henderson, C. (Investigator), Keyse, S. (Investigator), Lamond, A. (Investigator) & Sutherland, C. (Investigator)

  Medical Research Council

  1/05/16 → 31/10/19

  Project: Research

  • NFE2L2 100%
  • Nuclear Factor Erythroid 2-related Factor 2 (Nrf2) 98%
  • Transcription Factor 67%
  • Kelch-like 65%
  • Associated Proteins 65%

• Preliminary Evaluation of the Therapeutic Potential of Lithium in Mild Cognitive Impairment (Joint with Oxford University)

  Duthie, A. (Investigator) & Sutherland, C. (Investigator)

  1/09/15 → 30/06/17

  Project: Research

  • Glycogen Synthase Kinase 3 (GSK3) 100%
  • Lithium Treatment 57%
  • Bipolar Disorder 57%
  • Invited Commentary 52%
  • Retainment 52%

• Identification and Validation of the GSK3 Targets in the Heart

  Fuller, W. (Investigator) & Sutherland, C. (Investigator)

  British Heart Foundation

  1/09/12 → 31/08/15

  Project: Research

  • Glycogen Synthase Kinase 3 (GSK3) 100%
  • Glycogen Synthase Kinase 3 100%
  • Phosphorylation 85%
  • Adipocyte 50%
  • N-terminus 50%